Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 23, 2007

KaloBios Licenses Humaneering Technology to Novartis

  • KaloBios Pharmaceuticals’ granted Novartis a nonexclusive license its Humaneering™ technology. Novartis will use the platform to develop human antibodies.

    This is the first such nonexclusive technology transfer that KaloBios has offered for its Humaneering platform. As part of the transition plan, KaloBios has agreed to Humaneer three antibodies for Novartis in addition to the three that have been successfully completed as part of a pilot R&D relationship.

    "This nonexclusive license brings in sufficient new revenue to fund our clinical studies for KB001 (Pseudomonas infections) and our three clinical programs for KB002 (inflammation and autoimmune indications) into mid 2008," notes David Pritchard, KaloBios CEO.

    Humaneering is KaloBios’ method for converting nonhuman antibodies into engineered human antibodies for therapeutic drug applications. The system maintains epitope specificity and increases affinity, according to the company. The Humaneered antibodies are as close as, if not closer to, human germline sequences than the products of fully human antibody generation techniques.